HER-2 negative + AR positive + ER positive

P3, N=1560, Active, not recruiting, Fudan University | Recruiting --> Active, not recruiting | Trial completion date: Jul 2024 --> Jul 2027 | Trial primary completion date: Jul 2021 --> Jul 2026

Postoperative recovery was uneventful, and she remained recurrence-free on tamoxifen therapy for 2 years. This case highlights key imaging features suggestive of invasion in EPC, which may facilitate preoperative assessment and management.

Triple-phase DECT-derived parameter AEF was identified as a useful negativity predictor for ER and PR levels, while ERVE was demonstrated as a positivity predictor of HER2 status in invasive breast cancer.

P2, N=12, Not yet recruiting, Harbin medical university cancer hospital; Harbin medical university cancer hospital

We conducted a secondary analysis of the Stockholm tamoxifen (STO-5) randomized controlled trial (1990-1997) with 20-year complete follow-up, including 924 premenopausal women with operable breast cancer in Stockholm, Sweden...Patients with high PR heterogeneity significantly benefited from endocrine therapy (HR = 0.41; 95% CI, 0.24-0.71). These findings suggest that premenopausal patients with high PR heterogeneity have increased long-term risk but significantly benefit from endocrine therapy.

This case not only emphasizes the rarity of MBC but also draws attention to the exceptional phenomenon of SR in invasive carcinoma. Recognition of such rare events underscores the importance of cautious decision-making, multidisciplinary management, and further research into the biological and immunological mechanisms underlying tumor regression.

The diagnosis and treatment of metachronous malignancies, particularly involving the breast and rectum, are inherently complex. Optimal patient outcomes necessitate a comprehensive, coordinated, and individualized approach, emphasizing the importance of long-term surveillance and adaptable management strategies.

Endocrine resistance may be the cause of poor survival of NP and PN, and should be combined with other treatments such as actual intensive chemotherapy. Although the clinical number of NP breast cancer is small, it still needs attention.

P2, N=70, Recruiting, Criterium, Inc. | Trial completion date: Dec 2027 --> Dec 2028

P2, N=43, Recruiting, City of Hope Medical Center | Trial completion date: Aug 2025 --> Aug 2026 | Trial primary completion date: Aug 2025 --> Aug 2026

P2, N=52, Active, not recruiting, Borstkanker Onderzoek Groep | Trial completion date: Dec 2024 --> Nov 2025

Genetic testing was negative for BRCA1/2, CHEK2, and PALB2 mutations, though familial cancer history suggested a possible hereditary syndrome (FCC suspicion). This case underscores the complexity of managing multicentric breast cancer with discordant receptor status and raises questions about the role of biopsy sites in tumor development.